IDO Targeting in Sarcoma: Biological and Clinical Implications

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Sarcomas exhibit limited response to immunotherapy.
• Kynurenine Pathway (KP) activity increases in sarcoma patients treated with pembrolizumab.
• IDO1, a key KP enzyme, is a potential therapeutic target for immune escape.

Purpose of the Study:

• Investigate IDO1 expression in human sarcomas.
• Evaluate the preclinical efficacy of IDO1 blockade alone and combined with PD-L1 blockade in sarcoma.
• Elucidate mechanisms underlying IDO1 inhibitor response in sarcoma.

Main Methods:

• Immunohistochemistry for IDO1 and CD8 in 203 human sarcomas.
• Preclinical syngeneic sarcoma model to assess KP modulation upon PD-L1 blockade.
• In vivo studies using IDO inhibitor GDC-0919 alone and with anti-PD-L1 antibody.
• Analysis of tumor growth, immune cell infiltration, and gene expression.

Main Results:

• IDO1 expression observed in 39.1% of sarcomas, higher with CD8 infiltration.
• PD-L1 blockade showed anti-tumor effects and modulated KP enzymes.
• GDC-0919 decreased Kynurenine/Tryptophan ratio and tumoral Kynurenine.
• GDC-0919, alone or combined, did not improve anti-tumor activity or immune infiltrate.
• GDC-0919 altered gene expression, downregulating PVR and granzymes, upregulating INHBA and DTX4.

Conclusions:

• IDO1 expression is a potential biomarker in sarcomas.
• IDO1 inhibition alone or with PD-L1 blockade lacks anti-tumor efficacy in this model.
• IDO1 pathway may influence Natural Killer (NK) cell function, warranting further investigation.